Fibrinogen receptor antagonists for inhibiting aggregation of blood platelets

A fibrinogen receptor antagonist of the formula ##STR86## wherein:

• X is ##STR87## Y is ##STR88## wherein n=0-5 and j=0-3;
• Z is --CO.sub.2 R.sub.2, ##STR89## wherein R.sup.10 is C.sub.1-8 alkyl, aryl, arylC.sub.1-8 alkyl,
• u is C or N,
• v is C or N,
• R is
• hydrogen,
• C.sub.0-6 alkyl, either unsubstituted or substituted, with one or more groups selected from fluoro, chloro, bromo, iodo, hydroxyl, C.sub.1-5 alkylcarbonyl(C.sub.0-8 alkyl)amino, arylC.sub.1-5 alkylcarbonyl(C.sub.0-8 alkyl)amino, aryloxy, C.sub.1-10 alkoxy, C.sub.1-5 alkoxycarbonyl, C.sub.0-5 alkylaminocarbonyl, C.sub.1-5 alkylcarbonyloxy, C.sub.3-8 cycloalkyl, aryl, oxo, amino, C.sub.1-6 alkylaminocarbonyl, phenylC.sub.1-3 alkylamino, aminocarbonylC.sub.0-4 alkyl, C.sub.1-8 alkylsulfonyl(C.sub.0-8 alkyl)amino, aryl C.sub.0-10 alkylsulfonyl(C.sub.0-8 alkyl)amino, arylC.sub.0-8 alkylsulfonyl, C.sub.0-8 alkylsulfonyl, hydroxycarbonylC.sub.0-5 alkyl, C.sub.-8 alkyloxycarbonyl(C.sub.0-8 alkyl)amino, arylC.sub.0-10 alkyloxycarbonyl(C.sub.0-8 alkyl)amino, C.sub.0-8 alkylaminocarbonyl(C.sub.0-8 alkyl)amino, arylC.sub.0-8 alkylaminocarbonyl(C.sub.0-8 alkyl)amino, C.sub.0-8 alkylaminocarbonyloxy, arylC.sub.0-10 alkylaminocarbonyloxy, C.sub.0-8 alkylaminosulfonyl(C.sub.0-8 alkyl)amino, arylC.sub.0-8 alkylaminosulfonyl(C.sub.0-8 alkyl)amino, C.sub.0-8 alkylaminosulfonyl, and arylC.sub.0-8 alkylaminosulfonyl;
• provided that the carbon atom to which R or R.sup.1 is attached bear only one heteroatom;
• R.sup.1 is
• hydrogen,
• C.sub.0-6 alkyl, either unsubstituted or substituted, with one or more groups selected from fluoro, chloro, bromo, iodo, hydroxyl, C.sub.1-5 alkylcarbonyl(C.sub.0-8 alkyl)amino, arylC.sub.-5 alkylcarbonyl(C.sub.0-8 alkyl)amino, aryloxy, C.sub.1-10 alkoxy, C.sub.1-5 alkoxycarbonyl, C.sub.0-5 alkylaminocarbonyl, C.sub.1-5 alkylcarbonyloxy, C.sub.3-8 cycloalkyl, aryl, oxo, amino, C.sub.1-6 alkyl, C.sub.1-3 alkylamino, aminoC.sub.1-3 alkyl, arylC.sub.0-5 alkylaminocarbonyl, phenylC.sub.1-3 alkylamino, aminocarbonylC.sub.0-4 alkyl, C.sub.1-8 alkylsulfonyl(C.sub.0-8 alkyl)amino, aryl C.sub.0-10 alkylsulfonyl(C.sub.0-8 alkyl)amino, arylC.sub.0-8 alkylsulfonyl, C.sub.0-8 alkylsulfonyl, hydroxycarbonylC.sub.0-5 alkyl, C.sub.1-8 alkyloxycarbonyl(C.sub.0-8 alkyl)amino, arylC.sub.0-10 alkoxycarbonyl(C.sub.0-8 alkyl)amino, C.sub.0-8 alkylaminocarbonyl(C.sub.0-8 alkyl)amino, arylC.sub.0-8 alkylaminocarbonyl(C.sub.0-8 alkyl)amino, C.sub.0-8 alkylaminocarbonyloxy, arylC.sub.0-10 alkylaminocarbonyloxy, C.sub.0-8 alkylaminosulfonyl(C.sub.0-8 alkyl)amino, arylC.sub.0-8 alkylaminosulfonyl(C.sub.0-8 alkyl)amino, C.sub.0-8 alkylaminosulfonyl, and arylC.sub.0-8 alkylaminosulfonyl;
• provided that the carbon atom to which R or R.sup.1 is attached bear only one heteroatom;
• R.sup.2 is
• hydrogen,
• C.sub.1-12 alkyl, unsubstituted or substituted, with one or more C.sub.1-6 alkyl groups, ##STR90## where R.sup.9 is C.sub.1-6 alkyl, branched or unbranched, or phenyl, and wherein R.sup.9, when appearing more than once, can be the same or different;
• m is 1-4,
• or the pharmaceutically acceptable salts thereof, or optical isomer thereof.